• > About Us

    About Us

    Empowering Families With Precision Medicine For A Future of Personalized Genomic Solutions

    We will continue to be a company that sincerely cares about the future of each family and weaves the future of families with genome technology.

    Our Business

    Varinos is a clinical test company developing and providing new genomic test services.

    Our service

    We provide clinical tests in the field of reproductive medicine and obstetrics and gynecology, such as the "Endometrial Microbiome Test" which has been made possible by ourlatest genome technology to detect extremely small amounts of bacteria, and "Preimplantation Genetic Test" which examines the genes and chromosomes of an embryo before conception to check for abnormalities.

    Research and development area

    In addition to the fields of reproductive medicine and obstetrics and gynecology, we are expanding the use and potential of genomic medicine to include cancer and neonatal genetic diseases. We are developing unprecedented new genomic tests for the era of genomic medicine, where diagnosis is based on the diversity of genomes.

    Our goal is to standardize clinical test services using next-generation sequencers (NGS) and to provide clinical sequencing tests to patients in a timely manner.

    Genome is a word synthesized from genes and chromosomes; it is all the genetic information in DNA. Genome information is like a blueprint for building the body.Genome medicine is to diagnose and treat diseases efficiently and effectively based on the comprehensive genomic information.

    *NGS:Next Generation Sequencer
    Next-generation sequencer (NGS) is an instrument that can read thousands to millions of DNAsequences at high speed. It is possible to analyze the genome (genetic information) at an overwhelmingly low cost and in a short time.

    Our Technology

    • 01

      Swift Next-Gen Sequencing by Specialists

      The " Endometrial Microbiome Test," developed by our company, is the world's first practical application of microbiome technology in the infertility field using a next-generation sequencer as a clinical test.

    • 02

      Operation using in-house facilities

      Varinos Laboratory is a registered clinical laboratory (No. 177, Koto-ku, Tokyo), and implements unique quality control (QC) at key points in the Test process to minimize human error and ensure thorough accuracy control.

    • 03

      Research and development by our genome analysis specialists

      Our experienced specialists in next-generation sequencing develop new genomic tests. We are actively engaged in collaborative research with universities, research institutes, and IVF clinics throughout Japan.

    Our Service

    We develop and provide new clinical tests mainly in the fields of reproductive medicine and obstetrics and gynecology.

    Endometrial Microbiome Test business has continued since the company was founded.

    Endometrial microbiome Test uses specimens collected from the vagina and uterus to examine the types and percentages of bacteria in the uterus.

    Learn more about Endometrial Microbiome Test

    Lactoferrin, present in breast milk, plays a vital role in safeguarding both babies' and mothers' bodies from within. Varinos offers lactoferrin supplements.

    *We have obtained a patent for the invention of the use of lactoferrin for intrauterine flora.

    Learn more about Lactoferrin

    Preimplantation Embryo Genome Test and Analysis

    We offer the Preimplantation Genome Test (PGT-A), which allows us to evaluate the chromosomes of embryos after IVF or ICSI before implantation. This is a test project that uses genome analysis to examine chromosomal abnormalities, which are believed to be the cause of miscarriages before implantation.

    Our Story

    Varinos was founded by CEO Sakuraba and co-founder Nagai, who had extensive experience in the field of genetic testing and next-generation sequencing. Sakuraba had introduced the first new type of prenatal diagnosis (NIPT) in Japan and was involved in market development for genetic tests (NIPT and PGS) in obstetrics and gynecology. On the other hand, Nagai was a specialist in genetic statistical analysis and database construction. Having previously worked together at Illumina, a company that develops and markets next-generation sequencers, they established Varinos in 2017.

    Their motivation for founding Varinos stemmed from the observation that Japan lacked genome test companies, and tests that were commonplace in other countries were not available in Japan. Despite Japan's world-class research results in genomics, no company provided genomic tests as clinical tests in the medical field. This led Sakuraba and Nagai to embark on developing genomic tests in Japan, particularly focusing on providing services in the field of obstetrics and gynecology, with the aim of aiding patients in infertility treatment and supporting doctors in reproductive medicine who desired genomic testing but lacked access to it.

    The name "Varinos" is derived from "Variant for Diagnose," reflecting Nagai's aspiration to contribute to people's health by integrating genomics into society.

    "Our future goal is to be there for everyone, weaving the future of families."

    In the realm of reproductive medicine, where the success rate of a single IVF cycle is typically 10-30%, Varinos has dedicated efforts to develop and enhance genomic technology to increase success rates. Their vision is to create a world where fertility treatment patients can undergo reproductive medicine with an outstanding success rate of 70% to 80%. With this objective in mind, Varinos is committed to reducing the physical, financial, and psychological burdens faced by fertility treatment patients. They aim to support as many patients as possible, helping them pave the way for their family's future.

    Currently, our services primarily revolve around fertility treatment and reproductive medicine. However, this marks just the beginning of our journey. The potential of genome tests to shape the future of patients extends to various other domains, including neonatal diseases and cancer, where its capabilities can be harnessed for significant advancements.
    Emphasizing genome tests as our core foundation, we are dedicated to progressing and offering testing services across a diverse range of fields. Our commitment remains unwavering as we strive to unlock the full potential of genomic technology and contribute to the well-being of patients in numerous areas.

    Founding members

    Yoshiyuki Sakuraba
    Yoko Nagai

    Read more



    • Founder and CEO

      Yoshiyuki Sakuraba

      • 2001

        Received a Ph.D. (Science) from Saitama University in the post-doctoral program,Major in Genetics

      • 2001

        RIKEN Center for Genomic Sciences,Genome Related National Projects

      • 2008

        St. Jude Children's Hospital, USA
        Basic research on cancer-related genes

      • 2011

        Senior Manager, Laboratory Technology Department, GeneTech Corporation
        Development of detection method of chromosome aneuploidy using maternal blood nucleated erythrocytes
        Introduction of NIPT in Japan

      • 2014

        Exective Clinical Sales Specialist, Illumina, Inc.
        NIPT and PGT-A related technical sales
        Next generation sequencing for medical applications

      • 2017

        Founder and CEO, Varinos Inc. (present post)

    • Director, COO and CSO

      Yoichi Saito

      • 2008

        Graduated from Hokkaido University Faculty of Veterinary Medicine (Veterinarian)

      • 2008

        Astellas Pharma Inc.
        Responsible for clinical development in Japan and other Asian countries

      • 2013

        Business Producer, Dream Incubator Inc. 
        Engaged in consulting services for large companies and policy making support for government agencies.

      • 2016

        M3 Corporation
        Participated in the launch of the new Medical Marketer (MM) business as a main member and established the service.

      • 2018

        Executive Officer, Business Development, Preferred Networks, Inc.

      • 2020

        Director, COO and CSO, Varinos Inc. (current position)

    • Director, CFO

      Hidetoshi Hirakawa

      • 2006

        PwC Arata Limited Liability Audit Corporation (passed the Certified Public Accountant Examination)
        Worked as an in-charge at a megabank to support internal control evaluation

      • 2015

        Director and General Manager, Corporate Administration Division, GA technologies Inc.
        Achieved Mothers IPO in the 5th year after establishment and was in charge of M&A and IR after listing

      • 2019

        Director and CFO, Caster Inc.

      • 2020

        Director and CFO, RECLO Inc.

      • 2021

        Director, CFO, Varinos Inc. (current position)

    • Outside Director Tatsuzo Ishigami
    • Outside Director Yutaro Kasai
    • Outside Director Hiroyuki Misawa
    • Outside Director Jun Narimatsu
    • Outside Director Hiroko Kimura
    • Outside Director Huimin Wang
    • Auditor Masanori Ishikawa
    • Auditor Yoko sano

    Company Profile

    • Company name

      Varinos Inc.

    • Establishment date

      Feb. 20, 2017.

    • Business Description

      Contract analysis of clinical laboratories and development of genomic tests

    • Address

      1-1-20 Aomi, Koto-ku, Tokyo DiverCity Tokyo Office Tower 21F

    • TEL

      +81 3 5422 6501